Showing results (11-20 of 53) with videos related to
Sort By:
Pageof 6
Molecular Imaging and Biology|April 29, 2022
FDG PET/CT and Dosimetric Studies of 177Lu-Lilotomab Satetraxetan in a First-in-Human Trial for Relapsed Indolent non-Hodgkin Lymphoma-Are We Hitting the Target?Ayca Løndalen, Johan Blakkisrud, Mona-Elisabeth Revheim, et al.Acta Oncologica (Stockholm, Sweden)|August 24, 2021
Myelosuppression in patients treated with 177Lutetium-lilotomab satetraxetan can be predicted with absorbed dose to the red marrow as the only variableJohan Blakkisrud, Ayca Løndalen, Jostein Dahle, et al.Cell Cycle (Georgetown, Tex.)|August 29, 2015
New distinct compartments in the G2 phase of the cell cycle defined by the levels of γH2AXIdun Dale Rein, Caroline Stokke, Marwa Jalal, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 3, 2016
Red Marrow-Absorbed Dose for Non-Hodgkin Lymphoma Patients Treated with 177Lu-Lilotomab Satetraxetan, a Novel Anti-CD37 Antibody-Radionuclide ConjugateJohan Blakkisrud, Ayca Løndalen, Jostein Dahle, et al.EJNMMI Physics|August 21, 2023
Imaging of 212Pb in mice with a clinical SPECT/CTMonika Kvassheim, Anna Julie Kjøl Tornes, Asta Juzeniene, et al.EJNMMI Physics|March 8, 2020
EANM Dosimetry Committee series on standard operational procedures for internal dosimetry for 131I mIBG treatment of neuroendocrine tumoursJonathan Gear, Carlo Chiesa, Michael Lassmann, et al.European Journal of Nuclear Medicine and Molecular Imaging|February 23, 2018
Pre-dosing with lilotomab prior to therapy with 177Lu-lilotomab satetraxetan significantly increases the ratio of tumor to red marrow absorbed dose in non-Hodgkin lymphoma patientsCaroline Stokke, Johan Blakkisrud, Ayca Løndalen, et al.European Journal of Nuclear Medicine and Molecular Imaging|November 16, 2020
FDG PET/CT parameters and correlations with tumor-absorbed doses in a phase 1 trial of 177Lu-lilotomab satetraxetan for treatment of relapsed non-Hodgkin lymphomaAyca Løndalen, Johan Blakkisrud, Mona-Elisabeth Revheim, et al.Journal of Alzheimer'S Disease : JAD|November 15, 2021
Is Amyloid Burden Measured by 18F-Flutemetamol PET Associated with Progression in Clinical Alzheimer's Disease?Ebba Gløersen Müller, Trine Holt Edwin, Bjørn Heine Strand, et al.Seminars in Nuclear Medicine|January 12, 2023
Radioimmunotherapy of Non-Hodgkin B-cell Lymphoma: An updateFrancesco Cicone, Giulia Santo, Caroline Bodet-Milin, et al.Pageof 6